Friday, September 25, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 24, 2025

Communiqué de presse : Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline

View original at globenewswire.com
Communiqué de presse : Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Dynavax strengthens Sanofi's presence in adult vaccination by bringing differentiated vaccines that complement Sanofi's expertise

    80% confidence

  • This transaction and the attractive value it brings serves the best interests of the Company and its shareholders

    80% confidence

  • Sanofi's commercial presence, development capabilities and vision of science-based immunization will amplify opportunities for HEPLISAV-B and innovative pipeline to meet important public health needs

    80% confidence

  • The marketed adult hepatitis B vaccine and shingles vaccine candidate add new options to Sanofi's portfolio and underscore commitment to providing vaccine protection throughout life

    80% confidence

  • Joining Sanofi will bring the global scale and expertise needed to maximize the impact of Dynavax's vaccine portfolio

    80% confidence

  • The Dynavax acquisition agreement should not affect Sanofi's financial outlook for 2025

    80% confidence

  • Shingles affects one in three adults during their lifetime

    80% confidence

  • The acquisition is expected to close in Q1 2026, subject to satisfaction or waiver of customary closing conditions

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Go Mainstream, But Trustworthy Data Access Lags Adoption
A wave of enterprise AI agent activity — fresh funding (Latitude's $35M Series A), a run of CB Insights CEO interviews spotlighting fintech- and healthcare-focused agent startups (Covecta, Penguin AI, Maisa AI), and major platform partnerships (Microsoft-Mistral, Manulife-Microsoft AI governance, Siemens-NVIDIA agentic EDA, Box's agent security controls) — signals agentic AI moving from pilot to production across financial and enterprise workflows. Yet Google Cloud's own research shows adoption is outrunning data readiness (companies average AI access to only 45% of their data, with 'data laggards' capped near 30%), while insider selling at incumbent C3.ai hints at mixed investor conviction even as the broader ecosystem accelerates.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,983
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,983 facts checked against source5,305 source documents archived
Query this data → isubstrate.com
Communiqué de presse : Sanofi va acquérir Dynavax et ajouter un vaccin commercialisé contre l’hépatite B pour adultes et un candidat vaccin de phase 1⁄2 contre le zona au pipeline — Source | Via News | Via News